This Houston-based couple used their own experience of paying down consumer debt to launch a new company. Image courtesy of SpenDebt

Kiley and Ty'Lisha Summers once found themselves nearly $100,000 in debt; now, they have a goal of owning a $100 million company. The Houston-based couple used their own experience of paying down consumer debt to launch SpenDebt, a SaaS payment solution chosen for the Mastercard Start Path program.

You could say debt is ubiquitous in the United States. A 2015 report by The Pew Charitable Trusts found that 80 percent of American households have some form of debt. "As we started sharing our story, we realized that there were so many people who were just like us but didn't know what to do," explains Ty'Lisha, co-founder of SpenDebt.

SpenDebt's model relies on the simple truth: everyone spends money. The company, which is available as a phone app or web service, securely links to the user's bank account and allows you to designate a predetermined micropayment to be deducted at every transaction. The micropayments are then applied monthly to the debt of the user's choice, whether it be lofty student loans or a monthly car payment.

"God gave my husband the vision to start SpenDebt to help people help themselves," she says. Kiley even decided to share his concept Mastercard, but the idea was too early to gain anything other than the corporation's intrigue.

After two years of development and a subsequent year of beta testing, SpenDebt launched its commercialized product in 2019. The Summers applied to Mastercard Start Path, a highly competitive startup engagement program multiple times before being accepted into its 2021 cohort of six scaling startups.

"To finally get the 'yes,' it just made it full circle," says Ty'Lisha. "It's a game changer for SpenDebt."

Ty'Lisha Summers is the co-founder of SpenDebt. Photo courtesy

Fintech is a multibillion-dollar industry, and financial apps have become the darlings of venture capitalism. According to a SpenDebt release, companies that have participated in Start Path have gone on to raise more than $3 billion in post-program capital. Even while investor budgets were trimmed during the pandemic, Fintech companies garnered $44 billion in investments — a 14 percent increase since 2019, reports Finextra.

From the New Statesman to the Raconteur, media outlets and pundits have explored the saturation of the fintech sector. Ty'Lisha is confident that SpenDebt is different from its competitors.

"What's unique is that we give our customers 100 percent control on defining what that micropayment is, unlike our competition where it is strictly just round-up," she explains. The average SpenDebt user has set a $1.70 micropayment, but the co-founders have seen payments set at anything from 50 cents to $25 per transaction.

Initiatives like Bank of America's Keep the Change rounds up each transaction to the nearest dollar amount, then puts that money into a savings account for you to pay your debt off — or not. McKinsey & Company survey reports that more than 50 percent of US consumers expect to spend extra as COVID-19 restrictions relax, with higher-income millennials intending to spend the most. According to CNBC, Gen Z shoppers are also predicted to spend big on niceties like clothing and travel.

Though no app can automate personal discipline, SpenDebt can help you pay down debt and build financial literacy.

"With SpenDebt, once you tell us where you want that payment to go, that's where it's going," explains Ty'Lisha. When the micropayments are deducted from your account, SpenDebt holds onto your accrued payments and sends them monthly to the creditor of your choice. Ty'Lisha notes the service can be canceled or put on hold.

NBC News reported that 46 percent of Americans wiped out their emergency funds in 2020 as they shuffled to make ends meet. States around the country, including Texas, even enacted moratoriums on utility shut-offs in response to the pandemic. In some industries, "businesses went from collecting full payments from people to not collecting anything" or accepting partial payments, she explains.

The pandemic highlighted an opportunity for SpenDebt to partner with enterprises to offer creative solutions for payments that help customers pay off existing debt while helping businesses collect "something versus nothing."

As SpenDebt includes enterprises in its long-term growth strategy, the company founders have also pledged to work with nonprofits.

For the Summerses, SpenDebt's mission surpasses their desire to live a debt-free life. "As a part of our debt-free journey, we couldn't help but become more well-versed in finances. We were on a quest to make our money work for us versus the other way around," shares Ty'Lisha.

As Black business owners, Kiley and Ty'Lisha want to focus on building generational wealth for their family's future and help SpenDebt users do the same. "We like to say that we want all of the generational curses that may have been passed down to us to stop with us, and to start creating generational wealth for our future," she explains.

"[Debt] doesn't just address the middle class; there are so many people across the spectrum in debt," says Ty'Lisha. "A lot of times, the low-to-moderate income communities get overlooked," she continues.

SpenDebt is a preferred partner of United Way of Greater Houston and recently penned a partnership with Impact Hub Houston — an incubator with a mission to empower entrepreneurs and small businesses to take on issues like sustainability, gender equality, and economic growth.

SpenDebt hopes to capture its first enterprise customer during its six-month StartPath program and hopes to one day become a $100 billion company. "The resources, the network, the knowledge that we're getting from Mastercard and their network, the exposure that we're getting—it's going to be huge," says Ty'Lisha.

Of the many goals for SpenDebt's future, she wants the company to be "a solution for communities that may have been overlooked."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.